Clinical Trials Logo

NPMc+ AML clinical trials

View clinical trials related to NPMc+ AML.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04689815 Recruiting - NPMc+ AML Clinical Trials

Oral Arsenic Trioxide for NPM1-mutated AML

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

A prospective open-label phase 2 study will be designed to assess the efficacy of oral arsenic trioxide plus azacitidine in preventing relapses in patients with NPM1-mutant AML. After screening and eligibility assessment, patients will receive treatment with oral arsenic trioxide plus azacitidine for 12 months. The recruitment period will last for 24 months and it will take approximately 36 months for study completion.